EPA Backs Off Factory Farm Regulation

Whether it’s a Democratic or a Republican administration, favoring corporate power over the well-being of the public seems to carry the day more often than not. What a disappointment this administration has been on these types of issues.

The Environmental Protection Agency is obliged under the Clean Water Act to monitor America’s waterways and shield them from the toxic runoff from factory farms. But the growth of that industry, and its courtroom tenacity, has far outstripped the E.P.A.’s efforts to restrict runoff from manure lagoons and feedlots.

Last year, the agency meekly withdrew two proposed rules. One would have gathered basic information from all factory farms. The other proposed rule would have expanded the number of such farms required to have a national pollution discharge permit. Fewer than 60 percent do now.

Then, last week, in yet another retreat, the agency announced that promised new regulations governing feedlot discharges nationally would not be forthcoming.

According to the E.P.A.’s own studies, agricultural runoff is the leading cause of impaired water quality. The amount of manure produced by factory farms is staggering. The agency estimates that those operations create between 500 million and 1 billion tons of manure, three times as much waste as humans produce in the United States. The task of keeping those hundreds of millions of tons of animal waste out of rivers, lakes and estuaries is enormous, clearly requiring a strong set of revised regulations for the handling of factory-farm waste, including provisions for tracking waste when it’s been moved offsite.

Right now, the patchwork of regulations — which assume a great deal of self-policing — suits the factory-farm industry all too well. So does the E.P.A.’s inability to gather even the most basic information about those farms.

 

40% Failure Rate on Hip Transplants: Executives Knew But Hid the Evidence

This level of corruption in the service of corporate profits is no surprise to anyone who follows developments in the drug and medical device industries. Still, if I step back a bit, it is nothing short of breathtaking.

THIS month, Johnson & Johnson is facing more than 10,000 lawsuits over an artificial hip that has been recalled because of a 40 percent failure rate within five years. Mistakes happen in medicine, but internal documents showed that executives had known of flaws with the device for some time, but had failed to make them public.

It would be nice to imagine that this kind of behavior is exceptional, but in reality, the entire evidence base for medicine has been undermined by a casual lack of transparency. Sometimes this is through a failure to report concerns raised by doctors and internal analyses, as was the case with Johnson & Johnson. More commonly, it involves the suppression of clinical trial results, especially when they show a drug is no good. These problems would be bad enough on their own, but they are compounded by a generation of “fake fixes” that have delivered false reassurance, and so prevent realistic public discussion.

The best evidence shows that half of all the clinical trials ever conducted and completed on the treatments in use today have never been published in academic journals. Trials with positive or flattering results, unsurprisingly, are about twice as likely to be published — and this is true for both academic research and industry studies.

Read the rest of the article. It actually gets worse.